Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds

PDS0101 plus pembrolizumab showed antitumor activity in ICI-naive HPV16-positive R/M HNSCC, according to the results of a phase II trial.

September 25, 2026

Vol.52 No.35

In Brief

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

Podcast

Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”

In last week’s issue of The Cancer Letter, Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial.

August 19, 2026

Clinical Guest Editorial

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

A patient recently asked me a question I suspect many thoracic surgeons will soon be hearing.

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial.

July 31, 2026

Vol.52 No.30

Drugs & Targets

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Alpha1H has received regulatory approval from the European Medicines Agency for its phase III clinical study of the therapy in bladder cancer. The approval represents a milestone for the clinical development of Alpha1H and provides a clear regulatory path toward a potential future marketing application in Europe.

July 24, 2026

Vol.52 No.29

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

YOU MAY BE INTERESTED IN

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”

Marketing hope before surgery: Does the new Keytruda commercial tell patients the whole story?

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

EMA approves phase III clinical study of Alpha1H bladder cancer therapy

Renew today!

Subscriber content

Never miss an issue!

Login